Mr. Fernández Sousa-Faro has been a Professor of Biochemistry at the Complutense University of Madrid and the University of Santiago de Compostela, he obtained an MBA from the IESE Business School in Madrid. Dr. Fernández Sousa-Faro has over 90 scientific articles and patents in the field of biochemistry, drug discovery and molecular biology. With more than 25 years of experience in the pharmaceutical industry, he has held positions within the executive management of ICI-Farma, Antibióticos, Zeltia and Pharma Mar.
He was a member of the Board of Directors of Antibiotics, Penibérica, Biolys, ICI-Farma, Pescanova, Transfesa, Cooper–Zeltia, ICI-Zeltia and Banco Guipuzcoano. He founded Pharma Mar in 1986 and is currently the Chairman of the Board of Directors and Executive President of Pharma Mar.
With almost 30 years of experience in the pharmaceutical industry, Ms. de Francia started working at Pharma Mar in 1988 where she held different positions within the finance department. In 2000, she was appointed Chief Financial Officer. She received an undergraduate degree in law and a master’s degree in business administration from Comillas Pontifical University.
Ms. Sopesén received her doctorate degree in Pharmacy from the Complutense University of Madrid in 1998; a training that she complemented in 2007 with a management development program from IESE. Her scientific career started in 1993 when she completed a training program at SmithKline Beecham Pharmaceuticals, (now GSK), a tenure that was followed by basic research work during her thesis project.
After founding and working as a Manager and Technical Director of Qualysite Consultores,from 2001 until 2005, Ms. Sopesén became Managing Director of Noscira in 2006, a company she joined as Director of Quality Control. She previously worked in a Spanish contract research organization (CRO) called Cibest (now SGS), where she held different positions within the Clinical Research Department.
Ms. Sopesén leads the department of Market Research and Development of Pharma Mar, and in May 2014 she became a member of the Board of Directors of the chemical business unit Xylazel. She is also an independent member of the Board of the biotechnological company Biocross since May 2013.
With 30 years experience in the pharmaceutical industry and a Degree in Business Administration and MBA from the University of Barcelona, Luis Mora began his career as the Financial Controller for Zambon, S.A. and Pharmazam, S.A. in Barcelona and later as Head of Finance for Zambón Portugal. From 1995-2000 he served as Financial Controller with the Antibióticos Group (Montedison), and as Board Member of Vitatene, in Milan, Italy.
He joined PharmaMar in 2000 as Chief Financial Officer and was appointed Managing Director in 2008.
Mr. Cuenca holds an undergraduate degree in Law and Business Legal Counseling from ICADE. He is currently General Counsel and Secretary of Pharma Mar, a position he also held at Zeltia since 2003. A year later he was appointed Secretary of the Board of Directors of Zeltia, Pharma Mar, and other companies from the Pharma Mar group, including Xylazel and Sylentis. Mr. Cuenca has been a member of the Board of Spanish Issuers since its foundation, and professor of the Chair of Capital Markets Law from San Pablo CEU University.
Between 2009 and 2014, he taught Civil Law for the Advanced Course in Airport and Aeronautical Business Management of San Pablo CEU University. He is a member of the panel of experts on the financial market established by the Spanish Securities and Exchange Commission in 2006.
Mr. Moreno holds the position of Director of Investor Relations and Capital Markets at Pharma Mar, a position he has also held at Zeltia since 2009. From 2002 until 2009, he was the co-founder and managing partner of the independent financial group Solventis. He was previously head of equity sales at Banco Espirito Santo Investment for three years after holding this same post for non-resident clients at Benito y Monjardín SVB. He started his career in capital markets in 1994 working in the research and marketing department of the Spanish Futures and Options Exchange (MEFF RF), developing financial derivatives.
Mr. Moreno received an undergraduate degree in Management and Business Administration from the University of Hertfordshire and a degree in Business Administration from the University of Barcelona. He also completed a management development program (PDG) from IESE and he holds a C.A.I.A. (Chartered Alternative Investment Analyst). He has been invited to teach courses on financial derivative products for Masters courses in financial markets offered by the University of Barcelona, as well as other related courses at the Abat Oliba CEU University, the Center for Financial Studies and MEFF.
With a Master’s in Financial Management from ESIC, he joined the Pharma Mar Group’s Finance team in May 1989. Since November 2011, he has been in charge of the Group’s Internal Audit department, supervising the internal control system for financial reporting. He was previously Chief Accountant at Zeltia (June 2002–Nov. 2011) and at Pharma Mar (Nov. 1994-June 2002), supporting the Group’s other subsidiaries.